1,277 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Monday’s Close
NVS Novartis AG $85.13 $197.65B N/A
Article Searches
Biogen Reports Interim Phase III Data on Diroximel Fumarate http://www.zacks.com/stock/news/422832/biogen-reports-interim-phase-iii-data-on-diroximel-fumarate?cid=CS-ZC-FT-422832 May 31, 2019 - Biogen (BIIB) announces new interim results from phase III EVOLVE-MS-1 study, which showed that the diroximel fumarate was generally well tolerated in people with relapsing MS.
Novartis (NVS) Reports Positive Phase III Data on Asthma Drug http://www.zacks.com/stock/news/422639/novartis-nvs-reports-positive-phase-iii-data-on-asthma-drug?cid=CS-ZC-FT-422639 May 31, 2019 - Novartis' (NVS) investigational, once-daily, fixed dose combination asthma candidate, containing indacaterol acetate and mometasone furoate, meets goals.
Bothered by the Price Tag of a $2.1 Million Drug? Read This Before Complaining Too Much https://www.fool.com/investing/2019/05/30/bothered-by-the-price-tag-of-a-24-million-drug-rea.aspx?source=iedfolrf0000001 May 30, 2019 - Novartis' new gene therapy, Zolgensma, may be the most expensive drug ever, but there's much more to the story.
Novartis Gets FDA Nod for Breast Cancer Drug & Gene Therapy http://www.zacks.com/stock/news/420120/novartis-gets-fda-nod-for-breast-cancer-drug-gene-therapy?cid=CS-ZC-FT-420120 May 27, 2019 - Novartis (NVS) obtains FDA approvals for a breast cancer drug and a gene therapy for pediatric patients.
Incyte (INCY) Receives FDA Nod for Label Expansion of Jakafi http://www.zacks.com/stock/news/420060/incyte-incy-receives-fda-nod-for-label-expansion-of-jakafi?cid=CS-ZC-FT-420060 May 27, 2019 - Incyte (INCY) obtains FDA approval for a third indication of lead drug, Jakafi, for the treatment of GVHD.
Can Novartis Convince Insurers a $2.1 Million Gene Therapy Is a Great Deal? https://www.fool.com/investing/2019/05/26/can-novartis-convince-insurers-a-21-million-gene-t.aspx?source=iedfolrf0000001 May 26, 2019 - Getting end payers on board with a seven-figure price for Zolgensma won't be easy.
Approval of a Game-Changing Gene Therapy for SMA Delivers a Win for Novartis and Regenxbio https://www.fool.com/investing/2019/05/24/approval-of-a-game-changing-gene-therapy-for-sma-d.aspx?source=iedfolrf0000001 May 24, 2019 - A $2.1 million price tag could make Zolgensma a blockbuster medicine for these companies.
Novartis Reports Data on Asthma Drug, Update from Annual Meet http://www.zacks.com/stock/news/418681/novartis-reports-data-on-asthma-drug-update-from-annual-meet?cid=CS-ZC-FT-418681 May 23, 2019 - Novartis (NVS) reports encouraging data on combination asthma drug. The company also highlights its growth plans at its annual meet.
Adverum Up as FDA Lifts Hold on Cohort of Wet AMD Study http://www.zacks.com/stock/news/417074/adverum-up-as-fda-lifts-hold-on-cohort-of-wet-amd-study?cid=CS-ZC-FT-417074 May 20, 2019 - Adverum's (ADVM) stock gains as the FDA lifts the clinical hold on the second cohort of an initial stage study on lead candidate.
KBC Group NV (KBCSF) CEO Johan Thijs on Q1 2019 Results - Earnings Call Transcript https://seekingalpha.com/article/4265007-kbc-group-nv-kbcsf-ceo-johan-thijs-q1-2019-results-earnings-call-transcript?source=feed_sector_transcripts May 17, 2019 - KBC Group NV (OTCPK:KBCSF) Q1 2019 Results Conference Call May 16, 2019 03:30 AM ET Company Participants Kurt De Baenst - Investor Relations Johan Thijs - CEO Rik Scheerlinck - CFO Conference Call Par

Pages: 12345678...128

<<<Page 3>